Evropská unie - estonština - EMA (European Medicines Agency)

acino pharma gmbh - klopidogreel - peripheral vascular diseases; stroke; myocardial infarction - antitrombootilised ained - klopidogreel on näidustatud aterotrombootiliste juhtumite ennetamiseks: * müokardiinfarkti (tekkinud mõni päev kuni 35 päeva): all kannatavatel patsientidel (alates 7 päeva kuni 6 kuud) või perifeersete arterite haigus. täiendava teabe jaoks vt osa 5.

Estonsko - estonština - Ravimiamet

g.l. pharma gmbh - rivaroksabaan - õhukese polümeerikattega tablett - 20mg 60tk; 20mg 10tk; 20mg 14tk; 20mg 45tk; 20mg 28tk; 20mg 90tk; 20mg 98tk

Estonsko - estonština - Ravimiamet

g.l. pharma gmbh - rivaroksabaan - õhukese polümeerikattega tablett - 10mg 45tk; 10mg 30tk; 10mg 90tk; 10mg 100tk; 10mg 5tk; 10mg 42tk; 10mg 60tk; 10mg 10tk

Estonsko - estonština - Ravimiamet

g.l. pharma gmbh - rivaroksabaan - õhukese polümeerikattega tablett - 15mg 30tk; 15mg 45tk; 15mg 10tk; 15mg 42tk; 15mg 14tk; 15mg 5tk; 15mg 90tk; 15mg 60tk; 15mg 100tk

Estonsko - estonština - Ravimiamet

venus pharma gmbh - tseftriaksoon - süste-/infusioonilahuse pulber - 2g 10tk; 2g 1tk; 2g 5tk

Estonsko - estonština - Ravimiamet

venus pharma gmbh - tseftriaksoon - süste-/infusioonilahuse pulber - 1g 1tk; 1g 10tk

Estonsko - estonština - Ravimiamet

venus pharma gmbh - imipeneem+tsilastatiin - infusioonilahuse pulber - 500mg+500mg 10tk; 500mg+500mg 5tk

Estonsko - estonština - Ravimiamet

g.l. pharma gmbh - sildenafiil - õhukese polümeerikattega tablett - 20mg 300tk; 20mg 90tk

Evropská unie - estonština - EMA (European Medicines Agency)

mylan pharmaceuticals limited - aripiprasool - schizophrenia; bipolar disorder - psühhoeptikumid - aripiprasool mylan pharma on näidustatud skisofreenia raviks täiskasvanutel ja noorukitel vanuses 15 aastat ja vanemad. aripiprasool mylan pharma on näidustatud ravi mõõduka kuni raske maniakaalse episoodi bipolaarne i häire ja ennetamise ning uue maniakaalse episoodi täiskasvanutel, kes on kogenud peamiselt maniakaalsed episoodid ja kelle maniakaalsed episoodid vastas, et aripiprasool ravi. aripiprasool mylan pharma on näidustatud ravi kuni 12 nädala jooksul mõõduka kuni raske maniakaalse episoodi bipolaarne i häire noorukitel vanuses 13 aastat ja vanemad.

Evropská unie - estonština - EMA (European Medicines Agency)

taw pharma (ireland) limited - klopidogreelvesinikkloriid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombootilised ained - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.